W K Kelly

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Histone deacetylase inhibitors: from target to clinical trials
    William K Kelly
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Investig Drugs 11:1695-713. 2002
  2. pmc Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 56:237-44. 2009
  3. ncbi request reprint Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:2098-107. 2003
  4. ncbi request reprint Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer
    W K Kelly
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, N Y 10021, USA
    Eur Urol 34:18-23. 1998
  5. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
  6. ncbi request reprint Chemotherapy for androgen- independent prostate cancer: myth or reality
    W K Kelly
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 2:394-401. 2000
  7. ncbi request reprint Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
    W K Kelly
    Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    J Clin Oncol 19:44-53. 2001
  8. ncbi request reprint Novel trial designs: which agents and how do we test them?
    William Kevin Kelly
    Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 60:109-13; discussion 113-4. 2002
  9. ncbi request reprint Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
    Wm Kevin Kelly
    Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:3578-88. 2003
  10. ncbi request reprint Bicalutamide for advanced prostate cancer: the natural versus treated history of disease
    H I Scher
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 15:2928-38. 1997

Research Grants

Detail Information

Publications31

  1. ncbi request reprint Histone deacetylase inhibitors: from target to clinical trials
    William K Kelly
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Expert Opin Investig Drugs 11:1695-713. 2002
    ..Several HDAC inhibitors are currently in clinical trials as anticancer agents and, in particular, hydroxamic acid-based HDAC inhibitors have shown activity against cancers at well-tolerated doses...
  2. pmc Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 56:237-44. 2009
    ..Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth...
  3. ncbi request reprint Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:2098-107. 2003
    ..The purpose is to determine a safe weekly dose of i.v. estramustine phosphate (EMP) to combine with weekly paclitaxel and monthly carboplatin in patients with advanced prostate cancer...
  4. ncbi request reprint Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer
    W K Kelly
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, N Y 10021, USA
    Eur Urol 34:18-23. 1998
    ..Recognition of this syndrome has introduced a non-toxic therapy for advanced prostate cancer patients and has had a dramatic impact on the interpretation and design of clinical trials in patients with 'hormone refractory disease'...
  5. pmc Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  6. ncbi request reprint Chemotherapy for androgen- independent prostate cancer: myth or reality
    W K Kelly
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Joan and Sanford Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 2:394-401. 2000
    ..These data suggest that prostate cancer is not as resistant to chemotherapy as it was once thought to be...
  7. ncbi request reprint Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
    W K Kelly
    Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    J Clin Oncol 19:44-53. 2001
    ..To determine the safety and activity of weekly paclitaxel in combination with estramustine and carboplatin (TEC) in patients with advanced prostate cancer...
  8. ncbi request reprint Novel trial designs: which agents and how do we test them?
    William Kevin Kelly
    Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 60:109-13; discussion 113-4. 2002
    ..Only with the appropriate selection of disease state, trial design, and endpoints will we be able to select the most promising regimens to move forward...
  9. ncbi request reprint Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
    Wm Kevin Kelly
    Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:3578-88. 2003
    ..To evaluate the safety, pharmacokinetics, and biological activity of suberoylanilide hydroxamic acid (SAHA) administered by 2-h i.v. infusion in patients with advanced cancer...
  10. ncbi request reprint Bicalutamide for advanced prostate cancer: the natural versus treated history of disease
    H I Scher
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 15:2928-38. 1997
    ..To determine the therapeutic effects of bicalutamide 200 mg in patients with prostate cancers of different hormone sensitivities...
  11. ncbi request reprint Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer
    M J Zelefsky
    Department of Radiation Oncology, Solid Tumor Service, Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 18:1936-41. 2000
    ..To assess the feasibility and tolerance of neoadjuvant and concomitant estramustine phosphate and vinblastine (EV) with high-dose three-dimensional conformal radiotherapy (3D-CRT) for patients with unfavorable-risk prostate cancer...
  12. ncbi request reprint The Collection of Indirect and Nonmedical Direct Costs (COIN) form: a new tool for collecting the invisible costs of androgen independent prostate carcinoma
    E J Sherman
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer 91:841-53. 2001
    ..Considering the potentially significant impact on total costs, DNM/IC data should be included in future cost-analysis studies of patients with AIPC and other diseases...
  13. ncbi request reprint Histone deacetylases and cancer: causes and therapies
    P Marks
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Rev Cancer 1:194-202. 2001
    ..HDAC inhibitors are proving to be an exciting therapeutic approach to cancer, but how do they exert this effect?..
  14. ncbi request reprint Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration
    O Smaletz
    Department of Medicine, Division of Solid Tumor, Memorial Sloan Kettering Cancer Center, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    Ann Oncol 14:1518-24. 2003
    ..We conducted a dose-escalation study to determine a safe dose of BMS-247550 to combine with EMP in patients with metastatic prostate cancer...
  15. ncbi request reprint Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Immunohistochem Mol Morphol 13:6-13. 2005
    ..These data support the dose selection of ongoing phase 2 studies of G3139 at 7 mg/kg/d and docetaxel 75 mg/m2...
  16. pmc Prostate cancer clinical trial end points: "RECIST"ing a step backwards
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:5223-32. 2005
    ..To relate clinical issues to the clinical manifestations of prostate cancers across disease states using the eligibility and outcome criteria defined by Response Evaluation Criteria in Solid Tumors (RECIST)...
  17. ncbi request reprint Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
    ..To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies...
  18. pmc Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
    ..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam...
  19. ncbi request reprint Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease
    James A Eastham
    Memorial Sloan Kettering Cancer Center, New York, New York 94115, USA
    Urology 62:55-62. 2003
    ..The trial will enroll approximately 700 men during a 48-month period. Patients will be observed for 84 months after study closure. The power to detect a 36% decrease in 5-year recurrence rates is 90%...
  20. ncbi request reprint Quantifying the amount of variation in survival explained by prostate-specific antigen
    David A Verbel
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2576-9. 2002
    ..Using a population-based approach, we explore the relationship between PSA and survival and generate a measure to demonstrate the amount of the variation in survival explained by PSA...
  21. ncbi request reprint Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer
    Michael J Morris
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:679-83. 2002
    ..To evaluate the safety and pharmacokinetics of BCL-2 antisense oligonucleotide (G3139) administered by prolonged i.v. infusion in patients with advanced cancer...
  22. ncbi request reprint Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements
    Gunnar Steineck
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Acta Oncol 41:668-74. 2002
    ..The results support the use of cytotoxic drugs in the relapsed setting and definitive trials are ongoing to prove any benefit to survival...
  23. doi request reprint Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  24. ncbi request reprint Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid
    William Kevin Kelly
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Oncol 2:150-7. 2005
    ..SAHA is one of the HDAC inhibitors most advanced in development. It is in phase I and II clinical trials for patients with both hematologic and solid tumors...
  25. ncbi request reprint Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
    Urology 60:1-6. 2002
  26. ncbi request reprint Histone deacetylase inhibitors
    Paul A Marks
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Adv Cancer Res 91:137-68. 2004
    ..2001; Kelly et al., 2002a,b; Piekarz et al., 2001; Wozniak et al., 1999)...
  27. ncbi request reprint Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Charles J Ryan
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 64:90-4. 2004
    ..To describe the 5-year outcomes of patients with high-risk localized prostate cancer treated with neoadjuvant estramustine and vinblastine followed by concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)...
  28. ncbi request reprint Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:537-56. 2004
    ..To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA)...
  29. ncbi request reprint Use of nomograms for predicting survival in patients with castrate prostate cancer
    Matt Galsky
    Department of Medicine, Joan and Sanford I Weill Medical College of Cornell University, New York, New York, USA
    Urology 62:119-27. 2003
    ..These models have improved our ability to predict the outcomes of patients with castrate metastatic disease. However, further work to identify novel prognostic markers to improve the accuracy of these predictions is needed...
  30. ncbi request reprint Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference
    Philip W Kantoff
    Lank Center for Genitourinary Oncology, Boston, Massachusetts, USA
    J Urol 178:S5-8; quiz S4. 2007
  31. ncbi request reprint Bisphosphonates for men with prostate cancer: sifting through the rubble
    William Kevin Kelly
    J Clin Oncol 21:4261-2. 2003

Research Grants1

  1. Development of Oral Suberoylanilide Hydroxamic Acid
    William Kelly; Fiscal Year: 2003
    ..e.p21WAF1) in tumors. Subsequently, these findings will be correlated with the clinical outcomes. ..